Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its rivals? We will compare Black Titan to similar businesses based on the strength of its earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Profitability
This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -51.37% | -912.81% | -63.16% |
Insider & Institutional Ownership
57.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 20.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | -$4.71 million | -0.61 |
| Black Titan Competitors | $225.75 million | -$53.25 million | -10.51 |
Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Black Titan has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.68, indicating that their average share price is 32% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Black Titan and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 100 | 199 | 219 | 12 | 2.27 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 129.33%. Given Black Titan’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its rivals.
Summary
Black Titan rivals beat Black Titan on 7 of the 13 factors compared.
Black Titan Company Profile
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
